The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Leishmania and human immunodeficiency virus coinfection: the first 10 years
Open accessAbstract
Over 850 Leishmania-human immunodeficiency virus (HIV) coinfection cases have been recorded, the majority in Europe, where 7 to 17% of HIV-positive individuals with fever have amastigotes, suggesting that Leishmania-infected individuals without symptoms will express symptoms of leishmaniasis if they become immunosuppressed. However, there are indirect reasons and statistical data demonstrating that intravenous drug addiction plays a specific role in Leishmania infantum transmission: an anthroponotic cycle complementary to the zoonotic one has been suggested. Due to anergy in patients with coinfection, L. infantum dermotropic zymodemes are isolated from patient viscera and a higher L. infantum phenotypic variability is seen. Moreover, insect trypanosomatids that are currently considered nonpathogenic have been isolated from coinfected patients. HIV infection and Leishmania infection each induce important analogous immunological changes whose effects are multiplied if they occur concomitantly, such as a Th1-to-Th2 response switch; however, the consequences of the viral infection predominate. In fact, a large proportion of coinfected patients have no detectable anti-Leishmania antibodies. The microorganisms share target cells, and it has been demonstrated in vitro how L. infantum induces the expression of latent HIV-1. Bone marrow culture is the most useful diagnostic technique, but it is invasive. Blood smears and culture are good alternatives. PCR, xenodiagnosis, and circulating-antigen detection are available only in specialized laboratories. The relationship with low levels of CD4+ cells conditions the clinical presentation and evolution of disease. Most patients have visceral leishmaniasis, but asymptomatic, cutaneous, mucocutaneous, diffuse cutaneous, and post-kala-azar dermal leishmaniasis can be produced by L. infantum. The digestive and respiratory tracts are frequently parasitized. The course of coinfection is marked by a high relapse rate. There is a lack of randomized prospective treatment trials; therefore, coinfected patients are treated by conventional regimens. Prophylactic therapy is suggested to be helpful in preventing relapses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, H. C., Masur, H., Edgar, L. C., Whalen, G., Rook, A. H., & Fauci, A. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308253090803 · Cited by 1,600
A TH1→TH2 switch is a critical step in the etiology of HIV infection
Clerici, M., & Shearer, G. M. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90208-3 · Cited by 1,390
The Regulation of Immunity to Leishmania major
Reiner, S. L. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.151 · Cited by 1,297
Cytokine-Induced Expression of HIV-1 in a Chronically Infected Promonocyte Cell Line
Folks, T. M., Justement, J., Kinter, A., Dinarello, C. A., & Fauci, A. S. (1987) · Science · doi:10.1126/science.3313729 · Cited by 905
Folks, T. M., Clouse, K. A., Justement, J., Rabson, A., Duh, E., Kehrl, J. H., & Fauci, A. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2365 · Cited by 712
Taxonomy of Leishmania.Use of isoenzymes. Suggestions for a new classification
Rioux, J. A., Lanotte, G., Serres, E., Pratlong, F., Bastien, P., & Perieres, J. (1990) · Annales de Parasitologie Humaine et Comparée · doi:10.1051/parasite/1990653111 · Cited by 533
Scott, P. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.9.3149 · Cited by 524
Maggi, E., Mazzetti, M., Ravina, A., Annunziato, F., de Carli, M., Piccinni, M. P., Manetti, R., Carbonari, M., Pesce, A. M., del Prete, G., et al. (1994) · Science · doi:10.1126/science.8023142 · Cited by 495
New Perspectives on a Subclinical Form of Visceral Leishmaniasis
Badaro, R., Jones, T. C., Carvalho, E. M., Sampaio, D., Reed, S. G., Barral, A., Teixeira, R., & Johnson, W. D. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/154.6.1003 · Cited by 480
Lack of Evidence for the Dichotomy of T H 1 and T H 2 Predominance in HIV-Infected Individuals
Graziosi, C., Pantaleo, G., Gantt, K. R., Fortin, J.-P., Demarest, J. F., Cohen, O. J., Sékaly, R. P., & Fauci, A. S. (1994) · Science · doi:10.1126/science.8023143 · Cited by 424
Cited by
Burza, S., Croft, S. L., & Boelaert, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31204-2 · Cited by 1,913
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity
Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M., & Sacks, D. L. (2002) · Nature · doi:10.1038/nature01152 · Cited by 1,725
Drug Resistance in Leishmaniasis
Croft, S. L., Sundar, S., & Fairlamb, A. H. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.111-126.2006 · Cited by 1,663
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., Alvar, J., & Boelaert, M. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1748 · Cited by 1,490
Self-citationHerwaldt, B. L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10178-2 · Cited by 1,229
The increase in risk factors for leishmaniasis worldwide
Desjeux, P. (2001) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(01)90223-8 · Cited by 1,043
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Cañavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., López-Vélez, R., & Moreno, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00061-07 · Cited by 937
Self-citationLeishmaniasis– current chemotherapy and recent advances in the search for novel drugs
Croft, S. L., & Coombs, G. H. (2003) · Trends in Parasitology · doi:10.1016/j.pt.2003.09.008 · Cited by 891
Sundar, S., More, D. K., Singh, M. K., Singh, V. P., Sharma, S., Makharia, A., Kumar, P. C. K., & Murray, H. W. (2000) · Clinical Infectious Diseases · doi:10.1086/318121 · Cited by 664
Belkaid, Y., Hoffmann, K. F., Mendez, S., Kamhawi, S., Udey, M. C., Wynn, T. A., & Sacks, D. L. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.10.1497 · Cited by 557
“Such latent infections often give rise to severe forms of reactivation disease, including visceral leishmaniasis (VL) associated with, for example, HIV co-infection (3); the development of postkala-azar dermal leishmaniasis (PKDL) after cure of VL (4); reactivation of former skin lesions, termed recidivans type (5); a…”
Leishmaniasis emergence in Europe
Ready, P. D. (2010) · Eurosurveillance · doi:10.2807/ese.15.10.19505-en · Cited by 457
Alvar, J., Cañavate, C., Molina, R., Moreno, J., & Nieto, J. (2004) · Advances in Parasitology · doi:10.1016/s0065-308x(04)57001-x · Cited by 431
Self-citationMarine natural products and their potential applications as anti-infective agents
Donia, M., & Hamann, M. T. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00655-8 · Cited by 425
Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions
Haldar, A. K., Sen, P., & Roy, S. (2011) · Molecular Biology International · doi:10.4061/2011/571242 · Cited by 408
Leishmania/HIV co-infections: epidemiology in Europe
Desjeux, P., & Alvar, J. (2003) · Annals of Tropical Medicine & Parasitology · doi:10.1179/000349803225002499 · Cited by 398
Self-citationComplexities of Assessing the Disease Burden Attributable to Leishmaniasis
Bern, C., Maguire, J. H., & Alvar, J. (2008) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000313 · Cited by 368
Self-citationLeishmania infections: Molecular targets and diagnosis
Akhoundi, M., Downing, T., Votýpka, J., Kuhls, K., Lukeš, J., Cannet, A., Ravel, C., Marty, P., Delaunay, P., Kasbari, M., et al. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.11.012 · Cited by 363
Leishmaniasis in immunosuppressed individuals
van Griensven, J., Carrillo, E., López-Vélez, R., Lynen, L., & Moreno, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12556 · Cited by 348
Self-citationEpidemiological Evidence for Dormant Cryptococcus neoformans Infection
Garcia-Hermoso, D., Janbon, G., & Dromer, F. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.10.3204-3209.1999 · Cited by 323
An update on pharmacotherapy for leishmaniasis
Sundar, S., & Chakravarty, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.973850 · Cited by 320
le Fichoux, Y., Quaranta, J.-F., Aufeuvre, J.-P., Lelievre, A., Marty, P., Suffia, I., Rousseau, D., & Kubar, J. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1953-1957.1999 · Cited by 315
Worldwide risk factors in leishmaniasis
Oryan, A., & Akbari, M. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2016.06.021 · Cited by 299
Mendez, S., Reckling, S. K., Piccirillo, C. A., Sacks, D., & Belkaid, Y. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040298 · Cited by 296
Drug resistance in leishmaniasis
Chakravarty, J., & Sundar, S. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62887 · Cited by 270
Leishmaniasis: an update of current pharmacotherapy
Sundar, S., & Chakravarty, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.755515 · Cited by 261
Persistence Without Pathology in Phosphoglycan-Deficient Leishmania major
Späth, G. F., Lye, L.-F., Segawa, H., Sacks, D. L., Turco, S. J., & Beverley, S. M. (2003) · Science · doi:10.1126/science.1087499 · Cited by 167
Mendonça-Filho, R. R., Rodrigues, I. A., Alviano, D. S., Santos, A. L. S., Soares, R. M. A., Alviano, C. S., Lopes, A. H. C. S., & do Socorro S. Rosa, M. (2004) · Research in Microbiology · doi:10.1016/j.resmic.2003.12.001 · Cited by 115
Metadata
- Authors
- Alvar, J., Cañavate, C., Gutiérrez-Solar, B., Jiménez, M., Laguna, F., López-Vélez, R., Molina, R., & Moreno, J.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 1997-04
- Volume
- 10
- Issue
- 2
- Pages
- 298-319
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2148589496
- Cited by
- 736
- References
- 51
- FWCI
- 42.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.